1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

BioNotebook: Denovo, Celimmune revive Lilly, Amgen programs; Malin invests in Serenus; J&J opens fourth incubator; Blueprint, Alexion partner

 
• By Mandy Jackson

What's old is new again as San Diego-based Denovo Biopharma has licensed a second failed Eli Lilly drug and Celimmune in Lebanon, New Jersey has licensed a monoclonal antibody that's been sitting on Amgen's shelf since 2008.

What's old is new again as San Diego-based Denovo Biopharma has licensed a second failed Eli Lilly drug and Celimmune in Lebanon, New Jersey has licensed a monoclonal antibody that's been sitting on Amgen's shelf since 2008.

Denovo obtained all rights to develop, manufacture and commercialize pomaglumetad methionil (DB103; formerly LY2140023), an oral glutamate 2 and 3 receptor agonist that Lilly abandoned in 2012 after the drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Almirall Looks To Dominate Across Derma Spectrum

 
• By Kevin Grogan

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

More from Therapy Areas

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.